Business Description
Ironwood Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US46333X1081
Share Class Description:
IRWD: Class ATotal Employee Number:
100Compare
Compare
Traded in other countries / regions
IRWD.USAI76.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2010-02-03Description
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.2 | |||||
Equity-to-Asset | -0.57 | |||||
Debt-to-Equity | -2.45 | |||||
Debt-to-EBITDA | 1.64 | |||||
Interest Coverage | 7.27 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | -1.96 | |||||
Beneish M-Score | -3.1 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -6.2 | |||||
3-Year EBITDA Growth Rate | -22.9 | |||||
3-Year EPS without NRI Growth Rate | -36.1 | |||||
3-Year FCF Growth Rate | -19.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 70.47 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 34.61 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 60.09 | |||||
9-Day RSI | 57.54 | |||||
14-Day RSI | 56.11 | |||||
3-1 Month Momentum % | 5.18 | |||||
6-1 Month Momentum % | -16.27 | |||||
12-1 Month Momentum % | 260.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.06 | |||||
Quick Ratio | 6.06 | |||||
Cash Ratio | 2.41 | |||||
Days Sales Outstanding | 88.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.9 | |||||
Shareholder Yield % | 7.68 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | 60.64 | |||||
Net Margin % | 33.36 | |||||
EBITDA Margin % | 62.08 | |||||
FCF Margin % | 47.66 | |||||
OCF Margin % | 47.66 | |||||
ROE % | Neg. Equity | |||||
ROA % | 34.99 | |||||
ROIC % | 47.16 | |||||
3-Year ROIIC % | 147.68 | |||||
ROC (Joel Greenblatt) % | 289.05 | |||||
ROCE % | 137.98 | |||||
Years of Profitability over Past 10-Year | 6 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 5.68 | |||||
Forward PE Ratio | 3.55 | |||||
PE Ratio without NRI | 5.61 | |||||
Price-to-Owner-Earnings | 4.31 | |||||
PS Ratio | 1.9 | |||||
Price-to-Free-Cash-Flow | 3.95 | |||||
Price-to-Operating-Cash-Flow | 3.95 | |||||
EV-to-EBIT | 4.34 | |||||
EV-to-Forward-EBIT | 10.05 | |||||
EV-to-EBITDA | 4.3 | |||||
EV-to-Forward-EBITDA | 9.99 | |||||
EV-to-Revenue | 2.67 | |||||
EV-to-Forward-Revenue | 5.41 | |||||
EV-to-FCF | 5.6 | |||||
Price-to-GF-Value | 0.96 | |||||
Price-to-Projected-FCF | 0.48 | |||||
Price-to-Median-PS-Value | 0.41 | |||||
Earnings Yield (Greenblatt) % | 23.04 | |||||
FCF Yield % | 25.7 |
Ironwood Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ironwood Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 82 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:30 | 4.15 (-4.38%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 4.15 (-4.38%) | ||
| General meeting for 2026 | 2026-06-16 09:00 | 3.69 (-2.02%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 11:05 | 3.24 (-1.82%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:30 | 4.83 (+1.05%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 4.83 (+1.05%) | ||
| The Citizens Life Sciences Conference | 2026-03-11 16:00 | 3.70 (+0.00%) | ||
| Annual report for 2025 | 2026-02-26 | 3.36 (-6.67%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-25 08:30 | 3.79 (+2.71%) |
Show
Entries
Guru Commentaries on NAS:IRWD
No articles.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers